Skip to content
10-K

Annual Report

Longboard Pharmaceuticals, Inc.

0000950170-24-029952

← back to feed
Filed
Mar 12, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2023 · Mar 8, 2024 36.02M sh
Shares Diluted FY 2023 · Dec 31, 2023 22.73M sh
Shares Diluted FY 2023 · Dec 31, 2022 17.15M sh
Operating Cash Flow FY 2023 · Dec 31, 2023 −$50.87M
Operating Cash Flow FY 2023 · Dec 31, 2022 −$38.06M
Short Term Investments FY 2023 · Dec 31, 2023 $34.17M
Short Term Investments FY 2023 · Dec 31, 2022 $56.81M
Cash And Equivalents FY 2023 · Dec 31, 2023 $14.33M
Cash And Equivalents FY 2023 · Dec 31, 2022 $10.78M
Stockholders Equity FY 2023 · Dec 31, 2023 $40.92M
Stockholders Equity FY 2023 · Dec 31, 2022 $61.47M
Stockholders Equity FY 2023 · Dec 31, 2021 $103.32M
Current Liabilities FY 2023 · Dec 31, 2023 $9.77M
Current Liabilities FY 2023 · Dec 31, 2022 $8.76M
Current Assets FY 2023 · Dec 31, 2023 $50.22M
Current Assets FY 2023 · Dec 31, 2022 $69.84M
Total Assets FY 2023 · Dec 31, 2023 $50.7M
Total Assets FY 2023 · Dec 31, 2022 $70.62M
Eps Diluted FY 2023 · Dec 31, 2023 −$2.39
Eps Diluted FY 2023 · Dec 31, 2022 −$2.56
Eps Basic FY 2023 · Dec 31, 2023 −$2.39
Eps Basic FY 2023 · Dec 31, 2022 −$2.56
Sga Expense FY 2023 · Dec 31, 2023 $13.01M
Sga Expense FY 2023 · Dec 31, 2022 $10.16M
Rd Expense FY 2023 · Dec 31, 2023 $43.75M
Rd Expense FY 2023 · Dec 31, 2022 $34.64M
Net Income FY 2023 · Dec 31, 2023 −$54.42M
Net Income FY 2023 · Dec 31, 2022 −$43.95M
Operating Income FY 2023 · Dec 31, 2023 −$56.76M
Operating Income FY 2023 · Dec 31, 2022 −$44.8M